Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risperidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR1D | P28221 | 2/20 | 1.00 |
| ▸ | HTR1B | P28222 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risperidone SCHEMBL16965766 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL29392548 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL5070793 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL5777424 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL20578557 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL5774262 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL28382198 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL29051431 | 0.96 | DRD2 (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL3623879 | 0.96 | HTR2A (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| SCHEMBL23696626 | 0.96 | DRD2 (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 48665 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4588477-B1 | PHARMACEUTICAL COMPOSITION COMPRISING NALTREXONE AND RISPERIDONE FOR USE IN PREVENTING CANNABIS RELAPSE | SHENZHEN SCIENCARE PHARMACEUTICAL CO LTD (CN) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122072257-A | Method for rapidly detecting poison in blood | 中国科学院大连化学物理研究所 | 2026-05-22 | — | — | CN | claimed |
| WO-2026102521-A1 | USE OF A PURINE COMPOUND FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MARVEL BIOTECHNOLOGY (CA) | 2026-05-21 | — | — | WO | claimed |
| CN-122055139-A | Novel compositions for the treatment of spinal muscular atrophy | 豪夫迈·罗氏有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-1995013799-A1 | PREPARATION OF BIODEGRADABLE MICROPARTICLES CONTAINING A BIOLOGICALLY ACTIVE AGENT | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 1995-05-26 | — | — | WO | claimed |
| WO-1994025460-A1 | RISPERIDONE PAMOATE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-11-10 | — | — | WO | claimed |
| EP-0489108-A4 | METHOD AND COMPOSITION FOR THE TREATMENT OF CUTANEOUS, OCULAR, AND MUCOSAL HYPERSENSITIVITY, INFLAMMATION, AND HYPERPROLIFERATIVE CONDITIONS USING TOPICAL PREPARATIONS OF SEROTONIN ANTAGONISTS | — | 1992-10-28 | — | — | EP | claimed |
| EP-0196132-B1 | 1,2-BENZISOXAZOL-3-YL AND 1,2-BENZISOTHIAZOL-3-YL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-12 | — | — | EP | claimed |
| EP-0489108-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF CUTANEOUS, OCULAR, AND MUCOSAL HYPERSENSITIVITY, INFLAMMATION, AND HYPERPROLIFERATIVE CONDITIONS USING TOPICAL PREPARATIONS OF SEROTONIN ANTAGONISTS. | BETH ISRAEL HOSPITAL (US) | 1992-06-10 | — | — | EP | claimed |
| WO-1991002497-A1 | TOPICAL NIFEDIPINE FOR CUTANEOUS, OCULAR, MUCOSAL HYPERSENSITIVITY, INFLAMMATORY AND HYPERPROLIFERATIVE CONDITIONS | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1991-03-07 | — | — | WO | claimed |
| WO-1991002527-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF CUTANEOUS, OCULAR, AND MUCOSAL HYPERSENSITIVITY, INFLAMMATION, AND HYPERPROLIFERATIVE CONDITIONS USING TOPICAL PREPARATIONS OF SEROTONIN ANTAGONISTS | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1991-03-07 | — | — | WO | claimed |
| US-4804663-A | PSYCHOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-02-14 | — | — | US | claimed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | claimed |
| CN-86101906-A | Process for preparing 1, 2 benzisoxazol-3-yl and 1, 2 benzisothiazol-3-yl derivatives | — | 1986-10-01 | — | — | CN | claimed |